

## I. Editorial Features

### IN THIS ISSUE...

i

### EDITORIAL NOTE

N. Lameire

2737

### EDITORIAL COMMENTS

#### Latest US KDOQI Anaemia Guidelines update—what are the implications for Europe?

I. C. Macdougall, K.-U. Eckardt and F. Locatelli

2738

#### Sevelamer: a promising but unproven drug

S. C. Palmer, J. C. Craig, G. F. M. Strippoli  
(See related article by B. Manns *et al.* Economic evaluation of sevelamer in patients with end-stage renal disease. *Nephrol Dial Transplant* 2007; 22: 2867–2878.)  
(See related article by M. Tonelli *et al.* Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients. *Nephrol Dial Transplant* 2007; 22: 2856–2866.)

2742

#### Randomized controlled trials in PD

P. G. Blake  
(See related article by K. S. Rabindranath *et al.* Automated vs continuous ambulatory peritoneal dialysis: a systematic review of randomized controlled trials. *Nephrol Dial Transplant* 2007; 22: 2991–2998.)

2746

#### Recombinant EPO production—points the nephrologist should know

W. Jelkmann

2749

#### Angiogenic factors in preeclampsia: so complex, so simple?

N. Berkane, G. Lefevre and A. Hertig

2753

#### Acute renal failure in HIV patients

H. Izzedine, A. Baumelou and G. Deray

2757

### EDITORIAL REVIEWS

#### Effects of fluoridation of community water supplies for people with chronic kidney disease

M. Ludlow, G. Luxton and T. Mathew

2763

#### Multifactorial intervention in metabolic syndrome targeting at prevention of chronic kidney disease—ready for prime time?

P. Korantzopoulos, M. Elisaf and H. J. Milionis

2768

### TRANSLATIONAL NEPHROLOGY

#### A breakthrough in diabetic nephropathy: the role of endothelial dysfunction

T. Nakagawa, M. Segal, B. Croker and R. J. Johnson

2775

#### Renal side effects of anti-VEGF therapy in man: a new test system

T. Ostendorf, A. S. De Vriese and J. Floege

2778

### HYPOTHESIS

#### In severe acute kidney injury, a higher serum creatinine is paradoxically associated with better patient survival

J. Cerdá, M. Cerdá, P. Kilcullen and J. Prendergast

2781

### SPECIAL FEATURE

#### Clinical research of kidney diseases II: problems of study design

P. Ravani, P. S. Parfrey, E. Dicks and B. J. Barrett

2785

### SHORT COMMUNICATION

#### High variation of individual soluble serum CD30 levels of pre-transplantation patients: sCD30 a feasible marker for prediction of kidney allograft rejection?

W. Altermann, G. Schlaf, A. Rothhoff and B. Seliger

2795

#### Coating with paclitaxel improves graft survival in a porcine model of haemodialysis graft stenosis

B. H. Lee, J. E. Lee, K. W. Lee, H. Y. Nam, H. J. Jeon, Y. J. Sung, J. S. Kim, H. J. Lim, J.-s. Park, J. Y. Ko and D. J. Kim

2800

## II. Scientific Papers

### ORIGINAL ARTICLES

#### EXPERIMENTAL NEPHROLOGY

#### Sodium intake determines the role of adenosine A2 receptors in control of renal medullary perfusion in the rat

L. Dobrowolski, E. Kompanowska-Jeziarska, A. Walkowska and J. Sadowski

2805

#### Ciclosporin-induced hypertension is associated with increased sodium transporter of the loop of Henle (NKCC2)

C. Esteva-Font, E. Ars, E. Guillen-Gomez, J. M. Campistol, L. Sanz, W. Jiménez, M. A. Knepper, F. Torres, R. Torra, J. A. Ballarín and P. Fernández-Llama

2810

#### Effects of NH<sub>4</sub>Cl-induced systemic metabolic acidosis on kidney mitochondrial coupling and calcium transport in rats

L. M. A. Bento, M. M. Fagian, A. E. Vercesi and J. A. R. Gontijo

2817

#### Iron availability and complex stability of iron hydroxyethyl starch and iron dextran—a comparative *in vitro* study with liver cells and macrophages

N. Ternes, B. Scheiber-Mojdehkar, G. Landgraf, H. Goldenberg and B. Sturm

2824

#### Parathyroid hormone stimulates the endothelial nitric oxide synthase through protein kinase A and C pathways

G. Rashid, J. Bernheim, J. Green and S. Benchetrit

2831

#### Inhibitory effects of matrix metalloproteinase inhibitor ONO-4817 on morphological alterations in chlorhexidine gluconate-induced peritoneal sclerosis rats

Y. Ro, C. Hamada, M. Inaba, H. Io, K. Kaneko and Y. Tomino

2838

### CLINICAL NEPHROLOGY

#### Insulin therapy and acute kidney injury in critically ill patients—a systematic review

G. Thomas, M. C. Rojas, S. K. Epstein, E. M. Balk, O. Liangos and B. L. Jaber

2849

#### Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients

M. Tonelli, N. Wiebe, B. Culleton, H. Lee, S. Klarenbach, F. Shrive and B. Manns for the Alberta Kidney Disease Network

(See related article by B. Manns *et al.* Economic evaluation of sevelamer in patients with end-stage renal disease. *Nephrol Dial Transplant* 2007; 22: 2867–2878.)  
(See related article by S. C. Palmer *et al.* Sevelamer: a promising but unproven drug. *Nephrol Dial Transplant* 2007; 22: 2742–2745.)

2856

#### Economic evaluation of sevelamer in patients with end-stage renal disease

B. Manns, S. Klarenbach, H. Lee, B. Culleton, F. Shrive and M. Tonelli

(See related article by M. Tonelli *et al.* Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients. *Nephrol Dial Transplant* 2007; 22: 2856–2866.)  
(See related article by S. C. Palmer *et al.* Sevelamer: a promising but unproven drug. *Nephrol Dial Transplant* 2007; 22: 2742–2745.)

2867

#### Incomplete distal renal tubular acidosis affects growth in children

A. P. Sharma, R. K. Sharma, R. Kapoor, A. Kornecki, S. Sural and G. Filler

2879

#### Adult and paediatric patients with minimal change nephrotic syndrome show no major alterations in glomerular expression of sulphated heparan sulphate domains

T. J. M. Wijnhoven, J. M. Geelen, M. Bakker, J. F. M. Lensen, A. L. W. M. M. Rops, A. B. Kramer, G. Navis, M. J. W. van den Hoven, J. van der Vlag, J. H. M. Berden, J. F. M. Wetzels, L. P. W. J. van den Heuvel, L. A. H. Monnens and T. H. van Kuppevelt

2886

**Use of GFR equations to adjust drug doses in an elderly multi-ethnic group—a cautionary tale**

J. Gill, R. Malyuk, O. Djurdjev and A. Levin 2894

**Serum erythropoietin concentrations and responses to anaemia in patients with or without chronic kidney disease**

F. Artunc and T. Rislér 2900

**High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients**

N. Voormolen, M. Noordzij, D. C. Grootendorst, I. Beetz, Y. W. Sijkens, J. G. van Manen, E. W. Boeschoten, R. M. Huisman, R. T. Krediet, F. W. Dekker and the PREPARE study group 2909

**History of acute coronary events during the predialysis phase of chronic kidney disease is a strong risk factor for major adverse cardiac events in patients initiating haemodialysis**

Y. Tanaka, N. Joki and H. Hase 2917

**Long-term outcome of repeated lead chelation therapy in progressive non-diabetic chronic kidney diseases**

D.-T. Lin-Tan, J.-L. Lin, T.-H. Yen, K.-H. Chen and Y.-L. Huang 2924

**Biomarker discovery with SELDI-TOF MS in human urine associated with early renal injury: evaluation with computational analytical tools**

K. J. A. Vanhoutte, C. Laarakkers, E. Marchiori, P. Pickkers, J. F. M. Wetzels, J. L. Willems, L. P. van den Heuvel, F. G. M. Russel and R. Masereeuw 2932

**DIALYSIS AND TRANSPLANTATION**

**Disturbed mineral metabolism is associated with muscle and skin complaints in a prospective cohort of dialysis patients**

M. Noordzij, E. W. Boeschoten, W. J. Bos, F. W. Dekker, P. M. Bossuyt, R. T. Krediet and J. C. Korevaar for the NECOSAD Study Group 2944

**In vitro and in vivo evaluation of an oscillometric device for monitoring blood pressure in dialysis patients**

C. A. Lodi, C. Estridge and C. Ghidini 2950

**Temperature and concentration distribution within the Genius® dialysate container**

S. Eloit, A. Dhondt, J. Vierendeels, D. D. Wachter, P. Verdonck and R. Vanholder 2962

**Trace element removal during in vitro and in vivo continuous haemodialysis**

M. D. Churchwell, D. A. Pasko, I. F. Btaiche, J. C. Jain and B. A. Mueller 2970

**The AN69 ST haemodialysis membrane under conditions of two different extracorporeal circuit rinse protocols—a comparison of thrombogenicity parameters**

P. Richtrova, K. Opatrny, Jr, L. Vit, F. Sefrna and R. Perlik 2978

**Religious beliefs and quality of life in an American inner-city haemodialysis population**

B. Ko, A. Khurana, J. Spencer, B. Scott, M. Hahn and M. Hammes 2985

**Automated vs continuous ambulatory peritoneal dialysis: a systematic review of randomized controlled trials**

K. S. Rabindranath, J. Adams, T. Z. Ali, C. Daly, L. Vale and A. M. MacLeod  
(See related article by P. G. Blake. Randomized controlled trials in PD. *Nephrol Dial Transplant* 2007; 22: 2746–2749.) 2991

**Increasing fill volume reduces cardiac performance in peritoneal dialysis**

P. Ivarsen, J. V. Povlsen and J. D. Jensen 2999

**High membrane transport status on peritoneal dialysis is not associated with reduced survival following transfer to haemodialysis**

K. J. Wiggins, S. P. McDonald, F. G. Brown, J. B. Rosman and D. W. Johnson 3005

**Chronic kidney disease stage in renal transplantation—classification using cystatin C and creatinine-based equations**

C. White, A. Akbari, N. Hussain, L. Dinh, G. Filler, N. Lepage and G. A. Knoll 3013

**Arterial stiffness and wave reflections in renal transplant recipients**

F. Verbeke, W. Van Biesen, P. Peeters, L. M. Van Bortel and R. C. Vanholder 3021

**Impact of kidney transplantation on sleep apnoea in patients with end-stage renal disease**

J. M. Beecroft, J. Zaltzman, R. Prasad, G. Meliton and P. J. Hanly 3028

**Cigarette smoking and chronic allograft nephropathy**

N. Zitt, B. Kollerits, U. Neyer, W. Mark, D. Heining, G. Mayer, F. Kronenberg and K. Lhotta 3034

**Transplant professionals vary in the long-term medical risks they communicate to potential living kidney donors: an international survey**

A. A. Housawi, A. Young, N. Boudville, H. Thiessen-Philbrook, N. Muirhead, F. Rehman, C. R. Parikh, A. Al-Obaidli, A. El-Triki and A. X. Garg for the Donor Nephrectomy Outcomes Research (DONOR) Network 3040

**III. Clinical Reports**

**BRIEF REPORTS**

**Open access World Wide Web resources on urogenital infections**

K. N. Fragoulis, K. Z. Vardakas and M. E. Falagas 3046

**On-demand strategy as an alternative to conventionally scheduled post-transplant immunoadsorptions after ABO-incompatible kidney transplantation**

J. Wilpert, M. Geyer, P. Pisarski, O. Drognitz, C. Schulz-Huotari, A. Gropp, H. Goebel, P. Gerke, S. Teschner, G. Walz and J. Donauer 3048

**Epoetin delta in the management of renal anaemia: results of a 6-month study**

K. J. Martin on behalf of the Epoetin Delta 3001 Study Group 3052

**TECHNICAL NOTES**

**A pitfall of glomerular sieving: profibrotic and matrix proteins derive from the Bowman's capsule and not the glomerular tuft in rats with renovascular hypertension**

O. M. Steinmetz, U. Panzer, S. Fehr, C. Meyer-Schwesinger, R. A. K. Stahl and U. O. Wenzel 3055

**How much is catheter flow influenced by the use of closed luer lock access devices?**

S. Eloit, J.-Y. De Vos, R. Hombroux and P. Verdonck 3061

**CASE REPORTS**

**End-stage disease of native kidneys in a patient with biopsy-proven Arndt-Gottron scleromyxoedema and recurrence in the transplanted kidney**

P. Peeters, M. Praet, B. Van Vlem, J.-M. Naeyaert and R. Vanholder 3065

**Outcome of kidney transplantation in familial juvenile hyperuricaemic nephropathy**

L. Labriola, K. Dahan and Y. Pirson 3070

**IV. Educational Features**

**TEACHING POINT**

**A wild zebra chase**

A. Woywodt, S. Hellweg, A. Schwarz, R. M. Schaefer and M. Mengel 3074

## NEPHROQUIZ

### Rapid deterioration of renal function in a long-term allograft recipient with recurrent IgA nephritis—is it the only cause?

C. Sommerer, R. Waldherr and C. Morath 3079

## IMAGES IN NEPHROLOGY

### Marked facial enlargement in secondary hyperparathyroidism

M. Benjelloun, F. Tarrass, L. Alaoui, G. Medkouri, K. Hachim, M. B. Gharbi and B. Ramdani 3082

### An unusual case of endocarditis in a dialysis patient

B. K. Siddiqui, P. Patel, A. Margaryan, M. Mansour and C. Baskin 3084

## V. Varia

## LETTERS AND REPLIES

### History of isothermic dialysis

H.-D. Polaschegg 3086

### Reply

F. Pizzarelli 3087

### Cinacalcet, paricalcitol, or both?

M. Cozzolino, A. Galassi and D. Brancaccio 3087

### Reply

M. D. Arenas 3087

### Significance of endotoxaemia in chronic kidney disease

T. Fujita 3088

### Reply

R. Pecoits-Filho, S. Goncalves, A. E. Stingham and M. C. Riella 3089

### Home BP for assessing haemodialysis hypertension

R. Agarwal 3089

### Reply

H. Moriya 3090

## LETTERS

### A benefit for renal function after early switch to liposomal amphotericin B from conventional formulation in empirical antifungal treatment

F. Isnard, P. Tilleul, J.-P. Laporte, P. Chevallier, A. Pigneux, A. Lafuma, L. Mahi and G. Deray 3090

### Assisted peritoneal dialysis—an evolving dialysis modality

E. A. Brown, M. Dratwa and J. V. Povlsen 3091

### Preparation of advanced glycation end products *in vitro*

F. Waanders, E. van den Berg, C. Schalkwijk, H. van Goor and G. Navis 3093

### Treatment with corticosteroids does not seem to benefit nephrogenic systemic fibrosis

H. Pieringer, B. Schmekal, O. Janko and G. Biesenbach 3094

## ANNOUNCEMENTS

3095